PBYI Q2 2021 Earnings — Puma Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena

PBYIPuma Biotechnology, Inc.

$299M

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$53M-24.4% YoY

Gross Profit

$41M77.6% margin

Operating Income

-$17M-31.2% margin

Net Income

-$5M-9.6% margin

EPS (Diluted)

$-0.13

QoQ Revenue Growth

-45.6%

Cash Flow

Operating Cash Flow

-$74,000

Free Cash Flow

-$74,000

Stock-Based Comp.

$18M

Balance Sheet

Total Assets

$260M

Total Liabilities

$231M

Stockholders' Equity

$29M

Cash & Equivalents

$90M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$53M	$71M	-24.4%
Gross Profit	$41M	$61M	-32.3%
Operating Income	-$17M	$7M	-333.3%
Net Income	-$5M	$3M	-250.4%

Revenue Segments

Product

$49M92%

Royalty

$4M8%

License

$250,0000%